Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses

References

• Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age[J]. Expert Rev Clin Immunol. 2017;13(10):1–10. doi:10.1080/1744666X.2017.1366315.
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I. A vaccine targeting mutant IDH1 in newly diagnosed glioma[J]. Nature. 2021;592(7854):463–468. doi:10.1038/s41586-021-03363-z.
   PubMed Web of Science ®Google Scholar
• Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development[J]. Expert Rev Vaccines. 2018;17(3):207–215. doi:10.1080/14760584.2018.1434000.
   PubMed Web of Science ®Google Scholar
• Saxena M, Van Der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines[J]. Nat Rev Cancer. 2021;21(6):360–378. doi:10.1038/s41568-021-00346-0.
   PubMed Web of Science ®Google Scholar
• Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses[J]. Front Immunol. 2019;10:8. doi:10.3389/fimmu.2019.00008.
   PubMed Web of Science ®Google Scholar
• Qin L, Zhang H, Zhou Y, Umeshappa CS, Gao H. Nanovaccine‐based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy[J]. Small. 2021;17(28):2006000. doi:10.1002/smll.202006000.
   Web of Science ®Google Scholar
• Das A, Ali N. Nanovaccine: an emerging strategy[J]. Expert Rev Vaccines. 2021;20(10):1273–1290. doi:10.1080/14760584.2021.1984890.
   PubMed Web of Science ®Google Scholar
• Wen R, Umeano AC, Kou Y, Xu J, Farooqi AA. Nanoparticle systems for cancer vaccine[J]. Nanomedicine (Lond). 2019;14(5):627–648. doi:10.2217/nnm-2018-0147.
   PubMed Web of Science ®Google Scholar
• Koirala P, Bashiri S, Toth I, Skwarczynski M. Current prospects in peptide-based subunit nanovaccines[J]. Methods Mol Biol. 2022;2412:309–338.
   PubMedGoogle Scholar
• Lu L, Duong VT, Shalash AO, Skwarczynski M, Toth I. Chemical conjugation strategies for the development of protein-based subunit nanovaccines[J]. Vaccines (Basel). 2021;9(6):563–588.
   Web of Science ®Google Scholar
• He X, Zhou S, Quinn B, Jahagirdar D, Ortega J, Abrams SI, Lovell JF. HPV-associated tumor eradication by vaccination with synthetic short peptides and particle-forming liposomes[J]. Small. 2021;17(11):e2007165. doi:10.1002/smll.202007165.
   PubMed Web of Science ®Google Scholar
• Cordeiro AS, Patil-Sen Y, Shivkumar M, Patel R, Khedr A, Elsawy MA. Nanovaccine delivery approaches and advanced delivery systems for the prevention of viral infections: from development to clinical application[J]. Pharmaceutics. 2021;13(12):2091. doi:10.3390/pharmaceutics13122091.
   PubMed Web of Science ®Google Scholar
• Yin WM, Li YW, Gu YQ, Luo M. Nanoengineered targeting strategy for cancer immunotherapy[J]. Acta Pharmacol Sin. 2020;41(7):902–910. doi:10.1038/s41401-020-0417-3.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns[J]. Nat Rev Immunol. 2010;10(11):787–796. doi:10.1038/nri2868.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, Zhao C-X, Mitter N, Yu C, Middelberg APJ. Nanoparticle vaccines[J]. Vaccine. 2014;32(3):327–337. doi:10.1016/j.vaccine.2013.11.069.
   PubMed Web of Science ®Google Scholar
• El-Sayed N, Korotchenko E, Scheiblhofer S, Weiss R, Schneider M. Functionalized multifunctional nanovaccine for targeting dendritic cells and modulation of immune response[J]. Int J Pharm. 2021;593:120123. doi:10.1016/j.ijpharm.2020.120123.
   PubMed Web of Science ®Google Scholar
• Wen R, Banik B, Pathak RK, Kumar A, Kolishetti N, Dhar S. Nanotechnology inspired tools for mitochondrial dysfunction related diseases[J]. Adv Drug Deliv Rev. 2016;99(Pt A):52–69. doi:10.1016/j.addr.2015.12.024.
   PubMedGoogle Scholar
• Hu X, Wu T, Bao Y, Zhang Z. Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense[J]. J Control Release. 2017;256:26–45. doi:10.1016/j.jconrel.2017.04.026.
   PubMed Web of Science ®Google Scholar
• Kim CG, Kye YC, Yun CH. The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8(+) T cell responses[J]. Pharmaceutics. 2019;11(11):612. doi:10.3390/pharmaceutics11110612.
   PubMed Web of Science ®Google Scholar
• Du G, Sun X. Engineering nanoparticulate vaccines for enhancing antigen cross-presentation[J]. Curr Opin Biotechnol. 2020;66:113–122. doi:10.1016/j.copbio.2020.06.015.
   PubMed Web of Science ®Google Scholar
• Cai T, Liu H, Zhang S, Hu J, Zhang L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy[J]. J Nanobiotechnology. 2021;19(1):389. doi:10.1186/s12951-021-01146-2.
   PubMed Web of Science ®Google Scholar
• Zhang L-X, Sun X-M, Jia Y-B, Liu X-G, Dong M, Xu ZP, Liu R-T. Nanovaccine’s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy. Nano Today. 2020;35:100923. doi:10.1016/j.nantod.2020.100923.
   Web of Science ®Google Scholar
• Chen W, Zuo H, Li B, Duan C, Rolfe B, Zhang B, Mahony TJ, Xu ZP. Clay nanoparticles elicit long-term immune responses by forming biodegradable depots for sustained antigen stimulation[J]. Small. 2018;14(19):e1704465. doi:10.1002/smll.201704465.
   PubMed Web of Science ®Google Scholar
• Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R. Advancements in prophylactic and therapeutic nanovaccines[J]. Acta Biomater. 2020;108:1–21. doi:10.1016/j.actbio.2020.03.020.
   PubMed Web of Science ®Google Scholar
• Gheibi Hayat SM, Darroudi M. Nanovaccine: a novel approach in immunization[J]. J Cell Physiol. 2019;234(8):12530–12536. doi:10.1002/jcp.28120.
   PubMed Web of Science ®Google Scholar
• Carmona-Ribeiro AM, Perez-Betancourt Y. Cationic nanostructures for vaccines design[J]. Biomimetics (Basel). 2020;5(3). doi:10.3390/biomimetics5030032.
   PubMedGoogle Scholar
• Mao L, Chen Z, Wang Y, Chen C. Design and application of nanoparticles as vaccine adjuvants against human corona virus infection[J]. J Inorg Biochem. 2021;219:111454. doi:10.1016/j.jinorgbio.2021.111454.
   PubMed Web of Science ®Google Scholar
• Kijanka G, Bee JS, Korman SA, Wu Y, Roskos LK, Schenerman MA, Slütter B, Jiskoot W. Submicron size particles of a murine monoclonal antibody are more immunogenic than soluble oligomers or micron size particles upon subcutaneous administration in mice[J]. J Pharm Sci. 2018;107(11):2847–2859. doi:10.1016/j.xphs.2018.06.029.
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Ito A, Sogo Y, Ohno T. Particle-Size-Dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy[J]. Acta Biomater. 2013;9(7):7480–7489. doi:10.1016/j.actbio.2013.03.031.
   PubMed Web of Science ®Google Scholar
• Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines[J]. J Clin Invest. 2016;126(3):799–808. doi:10.1172/JCI81083.
   PubMed Web of Science ®Google Scholar
• Palombo M, Deshmukh M, Myers D, Gao J, Szekely Z, Sinko PJ. Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery[J]. Annu Rev Pharmacol Toxicol. 2014;54(1):581–598. doi:10.1146/annurev-pharmtox-010611-134615.
   PubMedGoogle Scholar
• Benne N, Van Duijn J, Kuiper J, Jiskoot W, Slütter B. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines[J]. J Control Release. 2016;234:124–134. doi:10.1016/j.jconrel.2016.05.033.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Van Der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O’Neil CP, Lee LK, Swartz MA, Hubbell JA. Exploiting lymphatic transport and complement activation in nanoparticle vaccines[J]. Nat Biotechnol. 2007;25(10):1159–1164. doi:10.1038/nbt1332.
   PubMed Web of Science ®Google Scholar
• D’Amico C, Fontana F, Cheng R, Santos HA. Development of vaccine formulations: past, present, and future[J]. Drug Deliv Transl Res. 2021;11(2):353–372. doi:10.1007/s13346-021-00924-7.
   PubMed Web of Science ®Google Scholar
• Carmona-Ribeiro AM. Supramolecular nanostructures for vaccines[J]. Biomimetics (Basel). 2021;7(1). doi:10.3390/biomimetics7010006.
   PubMedGoogle Scholar
• Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, Orba Y, Kawaguchi A, Hasegawa H, Kajino K, Ninomiya T, et al. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo[J]. ACS Nano. 2013;7(5):3926–3938. doi:10.1021/nn3057005.
   PubMed Web of Science ®Google Scholar
• Li Y, Kroger M, Liu WK. Shape effect in cellular uptake of PEGylated nanoparticles: comparison between sphere, rod, cube and disk[J]. Nanoscale. 2015;7(40):16631–16646. doi:10.1039/C5NR02970H.
   PubMed Web of Science ®Google Scholar
• Florez L, Herrmann C, Cramer JM, Hauser CP, Koynov K, Landfester K, Crespy D, Mailander V. How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells[J]. Small. 2012;8(14):2222–2230. doi:10.1002/smll.201102002.
   PubMed Web of Science ®Google Scholar
• Huang X, Li L, Liu T, Hao N, Liu H, Chen D, Tang F. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo[J]. ACS Nano. 2011;5(7):5390–5399. doi:10.1021/nn200365a.
   PubMed Web of Science ®Google Scholar
• Heuts J, Jiskoot W, Ossendorp F, van der Maaden K. Cationic nanoparticle-based cancer vaccines[J]. Pharmaceutics. 2021;13(5):596. doi:10.3390/pharmaceutics13050596.
   PubMed Web of Science ®Google Scholar
• Carmona-Ribeiro AM. Biomimetic nanoparticles: preparation, characterization and biomedical applications[J]. Int J Nanomedicine. 2010;5:249–259. doi:10.2147/IJN.S9035.
   PubMed Web of Science ®Google Scholar
• Ahmad MZ, Ahmad J, Alasmary MY, Abdel-Wahab BA, Warsi MH, Haque A, Chaubey P. Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges[J]. Immunotherapy. 2021;13(6):491–507. doi:10.2217/imt-2020-0258.
   PubMed Web of Science ®Google Scholar
• Zamani P, Momtazi-Borojeni AA, Nik ME, Oskuee RK, Sahebkar A. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy[J]. J Cell Physiol. 2018;233(7):5189–5199. doi:10.1002/jcp.26361.
   PubMed Web of Science ®Google Scholar
• Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition[J]. Vaccine. 2004;22(15–16):1903–1913. doi:10.1016/j.vaccine.2003.11.008.
   PubMed Web of Science ®Google Scholar
• Le MQ, Carpentier R, Lantier I, Ducournau C, Fasquelle F, Dimier-Poisson I, Betbeder D. Protein delivery by porous cationic maltodextrin-based nanoparticles into nasal mucosal cells: comparison with cationic or anionic nanoparticles[J]. Int J Pharm X. 2019;1:100001. doi:10.1016/j.ijpx.2018.100001.
   PubMedGoogle Scholar
• Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes[J]. J Immunol. 2010;185(6):3426–3435. doi:10.4049/jimmunol.1001205.
   PubMed Web of Science ®Google Scholar
• Dong X, Liang J, Yang A, Qian Z, Kong D, Lv F. A visible codelivery nanovaccine of antigen and adjuvant with self-carrier for cancer immunotherapy[J]. ACS Appl Mater Interfaces. 2019;11(5):4876–4888. doi:10.1021/acsami.8b20364.
   PubMed Web of Science ®Google Scholar
• Nagy NA, De Haas AM, Geijtenbeek TBH, van Ree R, Tas SW, van Kooyk Y, de Jong EC. Therapeutic liposomal vaccines for dendritic cell activation or tolerance[J]. Front Immunol. 2021;12:674048. doi:10.3389/fimmu.2021.674048.
   PubMed Web of Science ®Google Scholar
• Lee YS, Radford KJ. The role of dendritic cells in cancer[J]. Int Rev Cell Mol Biol. 2019;348:123–178.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiang Y, Xin VW, Wang X-W, Peng X-C, Liu X-Q, Wang D, Li N, Cheng J-T, Lyv Y-N, et al. Dendritic cell biology and its role in tumor immunotherapy[J]. J Hematol Oncol. 2020;13(1):107. doi:10.1186/s13045-020-00939-6.
   PubMed Web of Science ®Google Scholar
• Qin M, Li M, Song G, Yang C, Wu P, Dai W, Zhang H, Wang X, Wang Y, Zhou D, et al. Boosting innate and adaptive antitumor immunity via a biocompatible and carrier-free nanovaccine engineered by the bisphosphonates-metal coordination[J]. Nano Today. 2021:37(15):158–170.
   Web of Science ®Google Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines[J]. Trends Immunol. 2006;27(12):573–579. doi:10.1016/j.it.2006.10.005.
   PubMed Web of Science ®Google Scholar
• Warrier VU, Makandar AI, Garg M, Sethi G, Kant R, Pal JK, Yuba E, Gupta RK. Engineering anti-cancer nanovaccine based on antigen cross-presentation[J]. Biosci Rep. 2019;39(10). doi:10.1042/BSR20193220.
   PubMedGoogle Scholar
• Rosalia RA, Cruz LJ, Van Duikeren S, Tromp AT, Silva AL, Jiskoot W, De Gruijl T, Lowik C, Oostendorp J, Van Der Burg SH, et al. CD40-Targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses[J]. Biomaterials. 2015;40:88–97. doi:10.1016/j.biomaterials.2014.10.053.
   PubMed Web of Science ®Google Scholar
• Luo Z, Wang C, Yi H, Li P, Pan H, Liu L, Cai L, Ma Y. Nanovaccine loaded with poly I:c and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo[J]. Biomaterials. 2015;38:50–60. doi:10.1016/j.biomaterials.2014.10.050.
   PubMed Web of Science ®Google Scholar
• Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo[J]. Annu Rev Immunol. 2005;23(1):975–1028. doi:10.1146/annurev.immunol.22.012703.104538.
   PubMedGoogle Scholar
• Collin M, Bigley V. Human dendritic cell subsets: an update[J]. Immunology. 2018;154(1):3–20. doi:10.1111/imm.12888.
   PubMed Web of Science ®Google Scholar
• Pearce EJ, Everts B. Dendritic cell metabolism[J]. Nat Rev Immunol. 2015;15(1):18–29. doi:10.1038/nri3771.
   PubMed Web of Science ®Google Scholar
• Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, Lee WP, Park S, Xu M, DeVoss J, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation[J]. Nat Immunol. 2014;15(2):161–167. doi:10.1038/ni.2795.
   PubMed Web of Science ®Google Scholar
• Platt CD, Ma JK, Chalouni C, Ebersold M, Bou-Reslan H, Carano RAD, Mellman I, Delamarre L. Mature dendritic cells use endocytic receptors to capture and present antigens[J]. Proc Natl Acad Sci U S A. 2010;107(9):4287–4292. doi:10.1073/pnas.0910609107.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Chen X, Pan C, He Y, Su R, Guo D, Yin S, Wang S, Zhou L, et al. Self-Assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response[J]. J Immunother Cancer. 2021;9(8):e003132. doi:10.1136/jitc-2021-003132.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu J, Ma B, Deng B, Leng X, Kong D, Liu L. A simple self-adjuvanting biomimetic nanovaccine self-assembled with the conjugate of phospholipids and nucleotides can induce a strong cancer immunotherapeutic effect[J]. Biomater Sci. 2021;9(1):84–92. doi:10.1039/D0BM01333A.
   PubMed Web of Science ®Google Scholar
• Ma L, Diao L, Peng Z, Jia Y, Xie H, Li B, Ma J, Zhang M, Cheng L, Ding D, et al. Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells[J]. Adv Mater. 2021;33(43):e2104849. doi:10.1002/adma.202104849.
   PubMed Web of Science ®Google Scholar
• Silva JM, Zupancic E, Vandermeulen G, Oliveira VG, Salgado A, Videira M, Gaspar M, Graca L, Préat V, Florindo HF. In vivo delivery of peptides and toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model[J]. J Control Release. 2015;198:91–103. doi:10.1016/j.jconrel.2014.11.033.
   PubMed Web of Science ®Google Scholar
• Wui SR, Ko A, Ryu JI, Sim E, Lim SJ, Park SA, Kim KS, Kim H, Youn H, Lee NG. The effect of a TLR4 agonist/cationic liposome adjuvant on varicella-zoster virus glycoprotein E vaccine efficacy: antigen presentation, uptake, and delivery to lymph nodes[J]. Pharmaceutics. 2021;13(3):390. doi:10.3390/pharmaceutics13030390.
   PubMed Web of Science ®Google Scholar
• Das A, Asad M, Sabur A, Didwania N, Ali N. Monophosphoryl lipid a based cationic liposome facilitates vaccine induced expansion of polyfunctional T cell immune responses against visceral leishmaniasis[J]. ACS Appl Bio Mater. 2018;1(4):999–1018.
   PubMedGoogle Scholar
• Tang Y, Fan W, Chen G, Zhang M, Tang X, Wang H, Zhao P, Xu Q, Wu Z, Lin X, et al. Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment[J]. Nano Today. 2021:40(18):159–163.
   Web of Science ®Google Scholar
• Yan P, Luo Y, Li X, Li Y, Wang Y, Wu J, Zhou S. A redox-responsive nanovaccine combined with A2A receptor antagonist for cancer immunotherapy[J]. Adv Healthc Mater. 2021;10(21):e2101222. doi:10.1002/adhm.202101222.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang L, Liu Y, Chen X, Liu Q, Jia J, Yang T, Qiu S, Ma G. Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation[J]. Biomaterials. 2014;35(23):6086–6097. doi:10.1016/j.biomaterials.2014.04.022.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu P, Zhuang Y, Li P, Jiang B, Pan H, Liu L, Cai L, Ma Y. Lymphatic-Targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory[J]. Vaccine. 2014;32(42):5475–5483. doi:10.1016/j.vaccine.2014.07.081.
   PubMed Web of Science ®Google Scholar
• Manspeaker MP, Thomas SN. Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy[J]. Adv Drug Deliv Rev. 2020;160:19–35. doi:10.1016/j.addr.2020.10.004.
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu X, Zhang P, Liu Y, Ran W, Cai Y, Wang J, Zhai Y, Wang G, Ding Y, et al. Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma[J]. Acta Pharm Sin B. 2019;9(5):1050–1060. doi:10.1016/j.apsb.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Hansen S, Lehr CM. Nanoparticles for transcutaneous vaccination[J]. Microb Biotechnol. 2012;5(2):156–167. doi:10.1111/j.1751-7915.2011.00284.x.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu X, Xiang D. Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines[J]. Drug Deliv. 2018;25(1):1319–1327. doi:10.1080/10717544.2018.1477857.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu S, Qin Y, Fan F, Zhang Z, Huang C, Ji W, Lu L, Wang C, Sun H, et al. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy[J]. Nano Lett. 2019;19(7):4237–4249. doi:10.1021/acs.nanolett.9b00030.
   PubMed Web of Science ®Google Scholar
• Zaman M, Good MF, Toth I. Nanovaccines and their mode of action[J]. Methods. 2013;60(3):226–231. doi:10.1016/j.ymeth.2013.04.014.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, Kong M, Qi Y, Tan S, Zhang Z. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma[J]. ACS Nano. 2015;9(7):6918–6933. doi:10.1021/acsnano.5b01042.
   PubMed Web of Science ®Google Scholar
• Venceslau-Carvalho AA, Teixeira De Pinho Favaro M, Ramos Pereira L, Rodrigues-Jesus MJ, Santos Pereira S, Andreata-Santos R, dos Santos Alves RP, Castro-Amarante MF, Bitencourt Rodrigues K, Ramos da Silva J, et al. Nano-Multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies[J]. Nanomedicine. 2021;37:102445. doi:10.1016/j.nano.2021.102445.
   PubMed Web of Science ®Google Scholar
• Zhu D, Hu C, Fan F, Qin Y, Huang C, Zhang Z, Lu L, Wang H, Sun H, Leng X, et al. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination[J]. Biomaterials. 2019;206:25–40. doi:10.1016/j.biomaterials.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Pan C, Wu J, Qing S, Zhang X, Zhang L, Yue H, Zeng M, Wang B, Yuan Z, Qiu Y, et al. Biosynthesis of self-assembled proteinaceous nanoparticles for vaccination[J]. Adv Mater. 2020;32(42):e2002940. doi:10.1002/adma.202002940.
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen[J]. J Control Release. 2010;142(2):180–186. doi:10.1016/j.jconrel.2009.10.022.
   PubMed Web of Science ®Google Scholar
• Qu Y, Wang L, Yin S, Zhang B, Jiao Y, Sun Y, Middelberg A, Bi J. Stability of engineered ferritin nanovaccines investigated by combined molecular simulation and experiments[J]. J Phys Chem B. 2021;125(15):3830–3842. doi:10.1021/acs.jpcb.1c00276.
   PubMed Web of Science ®Google Scholar
• Bai S, Jiang H, Song Y, Zhu Y, Qin M, He C, Du G, Sun X. Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy[J]. J Control Release. 2022;344:134–146. doi:10.1016/j.jconrel.2022.02.027.
   PubMed Web of Science ®Google Scholar
• Li AW, Sobral MC, Badrinath S, Choi Y, Graveline A, Stafford AG, Weaver JC, Dellacherie MO, Shih T-Y, Ali OA, et al. A facile approach to enhance antigen response for personalized cancer vaccination[J]. Nat Mater. 2018;17(6):528–534. doi:10.1038/s41563-018-0028-2.
   PubMed Web of Science ®Google Scholar
• Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, Yu H, Gan Y, Wang Y, Mei L, et al. Recent progress in drug delivery[J]. Acta Pharm Sin B. 2019;9(6):1145–1162. doi:10.1016/j.apsb.2019.08.003.
   PubMed Web of Science ®Google Scholar
• Zhu G, Mei L, Vishwasrao HD, Jacobson O, Wang Z, Liu Y, Yung BC, Fu X, Jin A, Niu G, et al. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy[J]. Nat Commun. 2017;8(1):1482. doi:10.1038/s41467-017-01386-7.
   PubMedGoogle Scholar
• Hu C, Yang X, Liu R, Ruan S, Zhou Y, Xiao W, Yu W, Yang C, Gao H. Coadministration of iRGD with multistage responsive nanoparticles enhanced tumor targeting and penetration abilities for breast cancer therapy[J]. ACS Appl Mater Interfaces. 2018;10(26):22571–22579. doi:10.1021/acsami.8b04847.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Xu HL, Han GW, Tao L-N, Lu Y, Zheng S-Y, Fang W-H, He F. A self-assembling nanoparticle: implications for the development of thermostable vaccine candidates[J]. Int J Biol Macromol. 2021;183:2162–2173. doi:10.1016/j.ijbiomac.2021.06.024.
   PubMed Web of Science ®Google Scholar
• Deshpande S, Masurkar ND, Girish VM, Desai M, Chakraborty G, Chan JM, Drum CL. Thermostable exoshells fold and stabilize recombinant proteins[J]. Nat Commun. 2017;8(1):1442. doi:10.1038/s41467-017-01585-2.
   PubMedGoogle Scholar
• Chen W, Jiang M, Yu W, Xu Z, Liu X, Jia Q, Guan X, Zhang W. CpG-based nanovaccines for cancer immunotherapy[J]. Int J Nanomedicine. 2021;16:5281–5299. doi:10.2147/IJN.S317626.
   PubMed Web of Science ®Google Scholar
• Liang Z, Cui X, Yang L, Hu Q, Li D, Zhang X, Han L, Shi S, Shen Y, Zhao W, et al. Co-Assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy[J]. Int J Pharm. 2021;608:121091. doi:10.1016/j.ijpharm.2021.121091.
   PubMedGoogle Scholar
• Li X, Narayanan S, Michaelis VK, Ong TC, Keeler EG, Kim H, Mckay IS, Griffin RG, Wang EN. Zeolite Y adsorbents with high vapor uptake capacity and robust cycling stability for potential applications in advanced adsorption heat pumps[J]. Microporous Mesoporous Mater. 2015;201:151–159.
   Web of Science ®Google Scholar
• Sun B, Gillard M, Wu Y, Wu P, Xu ZP, Gu W. Bisphosphonate stabilized calcium phosphate nanoparticles for effective delivery of Plasmid DNA to Macrophages[J]. ACS Appl Bio Mater. 2020;3(2):986–996. doi:10.1021/acsabm.9b00994.
   PubMedGoogle Scholar
• Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses[J]. Front Immunol. 2019;10:22. doi:10.3389/fimmu.2019.00022.
   PubMed Web of Science ®Google Scholar
• Marasini N, Giddam AK, Khalil ZG, Hussein WM, Capon RJ, Batzloff MR, Good MF, Toth I, Skwarczynski M. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery[J]. Nanomedicine (Lond). 2016;11(24):3223–3235. doi:10.2217/nnm-2016-0291.
   PubMed Web of Science ®Google Scholar
• Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogenassociated molecular patterns on biomaterials: a paradigm for engineering new vaccines[J]. Trends Biotechnol. 2011;29(6):294–306. doi:10.1016/j.tibtech.2011.02.004.
   PubMed Web of Science ®Google Scholar
• Aikins ME, Xu C, Moon JJ. Engineered nanoparticles for cancer vaccination and immunotherapy[J]. Acc Chem Res. 2020;53(10):2094–2105. doi:10.1021/acs.accounts.0c00456.
   PubMed Web of Science ®Google Scholar
• Fusciello M, Fontana F, Tahtinen S, Capasso C, Feola S, Martins B, Chiaro J, Peltonen K, Ylösmäki L, Ylösmäki E, et al. Artificially cloaked viral nanovaccine for cancer immunotherapy[J]. Nat Commun. 2019;10(1):5747. doi:10.1038/s41467-019-13744-8.
   PubMedGoogle Scholar
• Xie X, Feng Y, Zhang H, Su Q, Song T, Yang G, Li N, Wei X, Li T, Qin X, et al. Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy[J]. Bioact Mater. 2022;16:107–119. doi:10.1016/j.bioactmat.2022.03.008.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang H, Qiu W, Han Y, Liu H, Li Z. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy[J]. Bioact Mater. 2022;16:418–432. doi:10.1016/j.bioactmat.2021.12.029.
   PubMed Web of Science ®Google Scholar
• Li J, Huang D, Cheng R, Figueiredo P, Fontana F, Correia A, Wang S, Liu Z, Kemell M, Torrieri G, et al. Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors[J]. Adv Mater. 2022;34(9):e2108012. doi:10.1002/adma.202108012.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yao L, Cao W, Liu Y, Zhai W, Wu Y, Wang B, Gou S, Qin Y, Qi Y, et al. Dendritic cell targeting peptide-based nanovaccines for enhanced cancer immunotherapy[J]. ACS Appl Bio Mater. 2019;2(3):1241–1254. doi:10.1021/acsabm.8b00811.
   PubMedGoogle Scholar
• Shae D, Baljon JJ, Wehbe M, Christov PP, Becker KW, Kumar A, Suryadevara N, Carson CS, Palmer CR, Knight FC, et al. Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines[J]. ACS Nano. 2020;14(8):9904–9916. doi:10.1021/acsnano.0c02765.
   PubMed Web of Science ®Google Scholar
• Carson CS, Becker KW, Garland KM, Pagendarm HM, Stone PT, Arora K, Wang-Bishop L, Baljon JJ, Cruz LD, Joyce S, et al. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA[J]. J Control Release. 2022;345:354–370. doi:10.1016/j.jconrel.2022.03.020.
   PubMed Web of Science ®Google Scholar
• Stickdorn J, Stein L, Arnold-Schild D, Hahlbrock J, Medina-Montano C, Bartneck J, Ziß T, Montermann E, Kappel C, Hobernik D, et al. Systemically administered TLR7/8 agonist and antigen-conjugated nanogels govern immune responses against tumors[J]. ACS Nano. 2022;16(3):4426–4443. doi:10.1021/acsnano.1c10709.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang K, Huang Y, Zhang H, Zhou L, Li A, Sun Y. Photosensitizer-induced HPV16 E7 nanovaccines for cervical cancer immunotherapy[J]. Biomaterials. 2022;282:121411. doi:10.1016/j.biomaterials.2022.121411.
   PubMed Web of Science ®Google Scholar
• Xia H, Qin M, Wang Z, Wang Y, Chen B, Wan F, Tang M, Pan X, Yang Y, Liu J, et al. A pH-/enzyme-responsive nanoparticle selectively targets endosomal toll-like receptors to potentiate robust cancer vaccination[J]. Nano Lett. 2022;22(7):2978–2987. doi:10.1021/acs.nanolett.2c00185.
   PubMed Web of Science ®Google Scholar
• Song H, Su Q, Shi W, Huang P, Zhang C, Zhang C, Liu Q, Wang W. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy[J]. Acta Biomater. 2022;141:398–407. doi:10.1016/j.actbio.2022.01.004.
   PubMed Web of Science ®Google Scholar
• Chen J, Fang H, Hu Y, Wu J, Zhang S, Feng Y, Lin L, Tian H, Chen X. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy[J]. Bioact Mater. 2022;7:167–180. doi:10.1016/j.bioactmat.2021.05.036.
   PubMed Web of Science ®Google Scholar
• Xiong X, Zhao J, Pan J, Liu C, Guo X, Zhou S. Personalized nanovaccine coated with calcinetin-expressed cancer cell membrane antigen for cancer immunotherapy[J]. Nano Lett. 2021;21(19):8418–8425. doi:10.1021/acs.nanolett.1c03004.
   PubMed Web of Science ®Google Scholar
• Su R, Chong G, Dong H, Gu J, Zang J, He R, Sun J, Zhang T, Zhao Y, Zheng X, et al. Nanovaccine biomineralization for cancer immunotherapy: a NADPH oxidase-inspired strategy for improving antigen cross-presentation via lipid peroxidation[J]. Biomaterials. 2021;277:121089. doi:10.1016/j.biomaterials.2021.121089.
   PubMed Web of Science ®Google Scholar
• Luo Z, He T, Liu P, Yi Z, Zhu S, Liang X, Kang E, Gong C, Liu X. Self-Adjuvanted Molecular Activator (SeaMac) nanovaccines promote cancer immunotherapy[J]. Adv Healthc Mater. 2021;10(7):e2002080. doi:10.1002/adhm.202002080.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fan J, Skwarczynski M, Stephenson RJ, Toth I, Hussein WM. Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances[J]. biomaterials. 2022;17:869–900. doi:10.2147/IJN.S269986.
   Google Scholar
• Jiang J. Cell-penetrating peptide-mediated nanovaccine delivery[J]. Curr Drug Targets. 2021;22:896–912.
   PubMed Web of Science ®Google Scholar